Metoclopramide Noridem (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide blocks dopamine D2 receptors in the chemoreceptor trigger zone of the brain, reducing the emetic signal. In the gastrointestinal tract it enhances acetylcholine release, promoting coordinated gastric contractions that speed stomach emptying and improve motility.

The dose of Metoclopramide Noridem is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and route of administration. Healthcare professionals set the appropriate dose and duration according to current clinical guidelines.

Safety data for Metoclopramide in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Metoclopramide Noridem, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

The most common alternative antiemetic class is serotonin (5‑HT3) antagonists such as ondansetron. While ondansetron primarily blocks serotonin receptors, Metoclopramide adds a pro‑kinetic effect by enhancing gastric motility. Choice depends on the clinical scenario, patient tolerance, and specific contraindications.

Metoclopramide Noridem should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep the product in its original packaging until use to maintain stability and sterility.

Metoclopramide Noridem is supplied as an injectable solution for intramuscular (IM) or intravenous (IV) administration. The route, rate of infusion, and volume are determined by the prescriber and should follow aseptic technique and institutional protocols.

Serious risks include extrapyramidal reactions such as dystonia or akathisia, tardive dyskinesia with prolonged use, neuroleptic malignant syndrome, severe hypotension, and rare allergic reactions. Prompt recognition and discontinuation are essential if any of these events occur.

Metoclopramide is contraindicated in patients with known hypersensitivity to the drug, pheochromocytoma, severe depression, or in those receiving MAO inhibitors. Caution is also advised for individuals with Parkinson disease, seizure disorders, or a history of extrapyramidal reactions.